- Proprietary new class of small molecules targeting therapeutically validated integrin
(referred to as integrin "silencers")
- Most advanced compound entering IND-enabling studies.
- Clinical proof-of-concept planned in a severe immune-mediated orphan disease
(novel concept of immune checkpoint modulation).
- Series of back-up compounds identified (available to extend therapeutic horizon).
- Technology applicable to other members of the integrin receptor family.